OTSSP167 inhibits the expansion of human T-ALL in a xenograft model. (A) Body weight monitoring of C57BL/6 mice treated Monday to Friday with vehicle or OTSSP167 (10 mg/kg) for 2 weeks. (B) Complete blood count at the end of the 2-week treatment. (C) KOPT-K1 cells labeled with firefly luciferase were injected into NSG mice and randomized into 2 groups for treatment with vehicle or OTSSP167 (10 mg/kg). At the end of each week, leukemia was monitored by BLI (n=5 per group). (D) Photon flux from BLI images at the end of weeks 2 and 3 of treatment. (E) Kaplan-Meier survival analysis. ∗∗P < .01, ∗∗∗P < .001 two-tailed Student t test was used in (D). Log-rank test was used in (E). BLI, bioluminescence imaging